NeurAxis
Private Company
Total funding raised: $12.5M
Overview
NeurAxis is a commercial-stage medical device company pioneering neuromodulation therapies for disorders of gut-brain interaction (DGBIs), such as functional abdominal pain associated with IBS and functional dyspepsia. Its flagship product, IB-Stim, is an FDA-cleared device that uses percutaneous electrical nerve field stimulation (PENFS) applied behind the ear, representing a first-to-market, non-pharmacologic treatment option primarily for the pediatric and adolescent population. The company is actively expanding market access through insurance coverage policies and has recently secured significant FDA label expansions into adult populations. Financially, it is revenue-generating with strong growth, supported by strategic financing and a public listing.
Technology Platform
Percutaneous Electrical Nerve Field Stimulation (PENFS) delivered via a behind-the-ear device to modulate the gut-brain axis.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
NeurAxis's IB-Stim is first-to-market with its specific indication and approach, but it competes indirectly with a wide range of pharmacological treatments for IBS and functional dyspepsia, as well as other neuromodulation devices (e.g., vagus nerve stimulators) and behavioral therapies. Its key differentiation is its non-systemic, device-based profile focused on the pediatric population.